Human Immunoglobulin (pH4) for Intravenous Injection Market Size to Exceed USD 182.1 Bn by 2032

The Human Immunoglobulin (pH4) for Intravenous Injection Market, estimated at USD 78.37 Bn in 2025, is expected to exhibit a CAGR of 12.8% and reach USD 182.1 Bn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

The advent of partnerships, agreements, and alliances can drive the growth of the global human immunoglobulin ph4 for intravenous injection market over the forecast period. For instance, on April 6, 2020, major market players such as Biotest Pharmaceuticals Corporation, BPL, LFB, and Octapharma AG joined the alliance formed by CSL Behring and Takeda Pharmaceutical Company Limited for the development of plasma-derived therapy to treat COVID-19.

Global Human Immunoglobulin (pH4) for Intravenous Injection Market – Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2019 as "coronavirus disease 2019" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

COVID-19 affected the economy in three main ways:  by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems with regard to the transportation of drugs from one place to another.

COVID-19 had a positive impact on the global human immunoglobulin ph4 for intravenous injection market. This is because of an increasing number of product launches to treat COVID-19 over the forecast period. For instance, in November 2020, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for Casirivimab and imdevimab to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients. Casirivimab and Imdevimab recombinant neutralizing human immunoglobulin G1 (IgG1) monoclonal antibodies to the spike protein of SARS-CoV-2.

Global Human Immunoglobulin Ph4 For Intravenous Injection Market: Key Developments

Key players are accelerating their research and development activities in order to develop a treatment for the COVID-19 disease which is expected to boost the market growth during the forecast period.

For instance, on March 4, 2020, Takeda Pharmaceutical Company Limited- a Japan-based  multinational pharmaceutical company, informed the United States Congress that it is initiating the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG), TAK-888, to treat patients with COVID-19.

Browse 34 Market Data Tables and 33 Figures spread through 201 Pages and in-depth TOC on “Global Human Immunoglobulin Ph4 For Intravenous Injection Market”- Forecast to 2030, Human Immunoglobulin Ph4 For Intravenous Injection Market, By Type (IgG, IgA, and IgM), By Disease Indication (COVID-19, Primary Immunodeficiency Disease, Immune-mediated Thrombocytopenia, Kawasaki Disease, B Chronic lymphocytic Leukemia(B-CLL), and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/human-immunoglobulin-ph4-for-intravenous-injection-market-3790

Key Takeaways of the Global Human Immunoglobulin Ph4 For Intravenous Injection Market:

• The global human immunoglobulin (pH4) for intravenous injection market is expected to exhibit a CAGR of 12.8% during the forecast period owing to the viral disease outbreak. According to the World Health Organization, around 464,212 cases of coronavirus disease were reported in Europe on April 1, 2020.
• Among type, the IgG segment is expected to dominate the market over the forecast period owing to an increase in r&d activities. For instance, in a study, published in Transfusion Medicine- the official journal of the British Blood Transfusion Society, in December 2022, Intravenous Immunoglobulin (IVIG) appeared effective in chronic immune thrombocytopenic purpura (ITP). The study reported that IVIG effectively increased platelet counts with response rates similar to other comparable preparations.
• Among disease indication, COVID- 19 segment is estimated to dominate the market over the forecast period. For instance, according to the data published by WHO on June 15, 2023, globally, nearly 1.5 million new cases and 7,300 deaths were reported between 15 May to 11 June 2023.
• Major players operating in the global human immunoglobulin ph4 for intravenous injection market include Takeda Pharmaceutical Company Limited, Baxter, CSL, Bayer AG, Grifols, S.A, Octapharma Brasil Ltda, Shanghai RAAS Blood Products Co Ltd, Hualan Biological Engineering, Inc, Top Bio Group Co, Ltd (A subsidiary of China Biologic Products Holdings, Inc), China Resources Boya Bio-pharmaceutical Group Co Ltd, ADMA Biologics, Inc, Sinopharm Group Co. Ltd.